Upcoming Global Web Symposia
April 22, 201411 a.m. to 12:00 pm EDT
There are a variety of ways to study human cancer progression and test potential therapeutics using translational animal models. Choosing the right animal model is critical to transition preclinical success in mouse/rat studies to success in human patients. It is widely accepted that each animal model has advantages and disadvantages and in most cases a multidisciplinary approach is the best one. In this webinar we will define the criteria for a translational model, give a specific example of taking a multidisciplinary approach using breast cancer as an example, and then bring to light additional considerations when combining novel therapeutics with the current standards of care.
1. Intro to Biomodels and Overview of Translational Models
2. Taking a Multidisciplinary Approach to Preclinical Research Using Breast Cancer as an Example
3. 3D Vascular Imaging as a Terminal Endpoint
4. Modeling Efficacy with Toxicity
5. Additional Examples of Translational Models
Maria L. Mancini, Ph.D.Principal Investigator
313 Pleasant St
In 2011 Dr. Mancini joined Biomodels as a Principal Investigator designing preclinical research studies in the areas of cancer and cancer supportive care, radiation countermeasures, and inflammatory diseases. Her expertise is in tumor biology and cancer signaling pathways and has been working on developing more specialized tumor models for preclinical research.
Dr. Mancini received her Ph.D. in Molecular Genetics from the University of Maine in 2007 in the laboratory of Calvin Vary, PhD. Her doctoral work primarily focused on uncovering novel mechanisms of developmental angiogenesis through the use of genetics based animal models. Maria then accepted a post-doctoral appointment at Harvard Medical School/BIDMC in the laboratory of Alex Toker, Ph.D. from 2007-2011 where she generated a variety of transgenic mouse lines to study PI3K signaling in breast cancer progression.
David M. Weinstein, Ph.D.President & COO
420 E. South Temple, Ste 520
Salt Lake City, UT
Dr. Weinstein serves as Numira’s President and Chief Operating Officer and has over 20 years of experience in image processing and software development for biomedical imaging. The innovative 3D visualization and analytic tools developed by Dr. Weinstein’s team at Numira have supported leading pharmaceutical, biotech, and medical device companies in the areas of discovery research and efficacy evaluation. Prior to the acquisition by Numira, he was the President and Chief Technology Officer for Visual Influence, Inc., a company formed in 2001 to focus primarily on exporting technology from the University of Utah’s Scientific Computing and Imaging Institute to commercial applications. Additionally, Dr. Weinstein served as technical manager for the NIH NCRR Center for Integrative Biomedical Computing, within the Scientific Computing and Imaging Institute at the University of Utah. Dr. Weinstein received his Ph.D. in computer science from the University of Utah and B.S. degrees in computer science and mathematics from U.C. Berkeley.
Cost: No cost!
250 First Avenue Suite 300Needham, MA 02494P: 781.972.5400F: 781.972.5425E: firstname.lastname@example.org
biological therapeutic productsbiomarkers & diagnosticsbiopharma strategybioprocess & manufacturingchemistryclinical trials & translational medicinedrug & device safety
drug discovery & developmentdrug targetsgenomicshealthcareit & informaticstechnology & tools for life sciencetherapeutic indications
conferencesReports & Market Researchbarnett educational servicesHealthtech PublishingKnowledge Foundation professional services
executive teamtestimonialschi timelinemailing listcareers